Experience
AbbVie Inc.
Boehringer Ingelheim International GmbH
Represented AbbVie in Biologics Price Competition and Innovation (BPCIA) litigation related to Humira®.
AbbVie Inc. v. Boehringer Ingelheim International GmbH, 1:17-cv-01065, D. Del., Judge Goldberg
Sandoz Inc. v. Boehringer Ingelheim International GmbH et al.
Boehringer Ingelheim International GmbH et al.
Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.
Biogen International GmbH
AbbVie Inc.
AbbVie Inc.
AbbVie Inc. v. Roxane Laboratories Inc.
AbbVie Inc.
AbbVie Inc.
Honeywell International Inc. v. Wintek Corp.
Wintek Corp.
Biogen Int’l GmbH v. Amneal Pharmaceuticals LLC et al.
Biogen Int’l GmbH
Grünenthal GmbH et al. v. Alvogen Pine Brook, Inc. et al.
Grünenthal GmbH et al.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.